IL241209D0 - Polyethyleneglycol-modified lipid compounds - Google Patents

Polyethyleneglycol-modified lipid compounds

Info

Publication number
IL241209D0
IL241209D0 IL241209A IL24120915A IL241209D0 IL 241209 D0 IL241209 D0 IL 241209D0 IL 241209 A IL241209 A IL 241209A IL 24120915 A IL24120915 A IL 24120915A IL 241209 D0 IL241209 D0 IL 241209D0
Authority
IL
Israel
Prior art keywords
polyethyleneglycol
modified lipid
lipid compounds
compounds
modified
Prior art date
Application number
IL241209A
Other languages
Hebrew (he)
Other versions
IL241209A (en
Original Assignee
Protiva Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US50323903P priority Critical
Priority to PCT/CA2004/001677 priority patent/WO2005026372A1/en
Application filed by Protiva Biotherapeutics Inc filed Critical Protiva Biotherapeutics Inc
Publication of IL241209D0 publication Critical patent/IL241209D0/en
Publication of IL241209A publication Critical patent/IL241209A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use
IL241209A 2003-09-15 2015-09-06 Polyethyleneglycol-modified lipid compounds IL241209A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US50323903P true 2003-09-15 2003-09-15
PCT/CA2004/001677 WO2005026372A1 (en) 2003-09-15 2004-09-15 Polyethyleneglycol-modified lipid compounds and uses thereof

Publications (2)

Publication Number Publication Date
IL241209D0 true IL241209D0 (en) 2015-11-30
IL241209A IL241209A (en) 2019-02-28

Family

ID=34312435

Family Applications (3)

Application Number Title Priority Date Filing Date
IL174315A IL174315A (en) 2003-09-15 2006-03-14 Polyethyleneglycol–modified lipid compounds
IL241209A IL241209A (en) 2003-09-15 2015-09-06 Polyethyleneglycol-modified lipid compounds
IL264517A IL264517D0 (en) 2003-09-15 2019-01-28 Polyethyleneglycol-modified lipid compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL174315A IL174315A (en) 2003-09-15 2006-03-14 Polyethyleneglycol–modified lipid compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL264517A IL264517D0 (en) 2003-09-15 2019-01-28 Polyethyleneglycol-modified lipid compounds

Country Status (10)

Country Link
US (2) US7803397B2 (en)
EP (1) EP1664316B1 (en)
JP (1) JP4842821B2 (en)
KR (1) KR101164256B1 (en)
CN (1) CN1882693B (en)
AU (1) AU2004272646B2 (en)
CA (1) CA2551022C (en)
IL (3) IL174315A (en)
NZ (2) NZ581166A (en)
WO (1) WO2005026372A1 (en)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
CN101291653B (en) * 2003-07-16 2012-06-27 普洛体维生物治疗公司 Lipid encapsulated interfering rna
EP1766035B1 (en) 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
WO2005120152A2 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
CA2572439A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
WO2006020182A2 (en) * 2004-07-16 2006-02-23 Smart Medical Technologies, Llc Centrifuge system
JP2008509205A (en) * 2004-08-13 2008-03-27 アイシー・ベック・リミテッドIC Vec Limited Vector containing polymer-modified siRNA liposomes
GB0418172D0 (en) * 2004-08-13 2004-09-15 Ic Vec Ltd Vector
CA2587411A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
WO2006074546A1 (en) * 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
AU2006336384B2 (en) 2005-02-14 2010-12-16 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US20080095834A1 (en) * 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
WO2006118260A1 (en) * 2005-05-02 2006-11-09 The University Of Tokyo Electrostatic bonding type polymer vesicle
CA2616877C (en) 2005-07-27 2014-01-28 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
US7838658B2 (en) 2005-10-20 2010-11-23 Ian Maclachlan siRNA silencing of filovirus gene expression
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20100178272A1 (en) * 2006-08-08 2010-07-15 Klinische Pharmakologie Structure and use of 5'phosphate oligonucleotides
CA2660204A1 (en) * 2006-08-16 2008-02-21 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
AU2014200910B2 (en) * 2006-10-03 2017-02-09 Arbutus Biopharma Corporation Lipid containing formulations
CA2848238C (en) 2006-10-03 2016-07-19 Tekmira Pharmaceuticals Corporation Lipid containing formulations
EP2069500B1 (en) * 2006-10-04 2014-09-24 Centre National De La Recherche Scientifique (Cnrs) Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
JP5347510B2 (en) * 2007-02-05 2013-11-20 日本新薬株式会社 Polyethylene glycol derivative
US9273300B2 (en) * 2007-02-07 2016-03-01 Strike Bio, Inc Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
EP2036577A1 (en) * 2007-09-14 2009-03-18 mivenion GmbH Diagnostic materials for optical image-forming investigation based on nanoparticulate formulations
CN101918473A (en) * 2007-11-07 2010-12-15 犹他大学研究基金会 Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery
CA3043911A1 (en) 2007-12-04 2009-07-02 Arbutus Biopharma Corporation Targeting lipids
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
WO2009086558A1 (en) * 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
ES2638448T3 (en) 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid administration
US8304565B2 (en) * 2008-06-11 2012-11-06 Nian Wu PEG-lipid conjugates for liposomes and drug delivery
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010030730A1 (en) * 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
WO2010033247A2 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
PL2350043T3 (en) 2008-10-09 2014-09-30 Tekmira Pharmaceuticals Corp Improved amino lipids and methods for the delivery of nucleic acids
US20110223257A1 (en) * 2008-11-17 2011-09-15 Enzon Pharmaceuticals, Inc. Releasable fusogenic lipids for nucleic acids delivery systems
CN102231952A (en) * 2008-11-17 2011-11-02 安龙制药公司 Releasable cationic lipids for nucleic acids delivery systems
WO2010074935A1 (en) * 2008-12-22 2010-07-01 Ge Healthcare Limited Synthesis of obtaining modified polyethylene glycol intermediates
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
MX2011009724A (en) 2009-03-19 2011-10-14 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING.
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
AU2010226434A1 (en) * 2009-03-20 2011-10-13 Egen, Inc. Polyamine derivatives
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
SG174581A1 (en) 2009-03-27 2011-10-28 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (en) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション RNA interference-mediated inhibition of thymic stromal lymphocyte formation factor (TSLP) gene expression using small interfering nucleic acids (siNA)
EP2430168B1 (en) * 2009-05-16 2016-12-21 Kunyuan Cui Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
EP2437756A2 (en) * 2009-06-02 2012-04-11 Wu, Nian Pure peg-lipid conjugates
ES2613498T3 (en) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. New lipid formulations for the delivery of therapeutic agents to solid tumors
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
PL2474306T3 (en) * 2009-08-31 2017-06-30 Nanocarrier Co., Ltd. Particle composition and medicinal composition comprising same
EP2480668A2 (en) 2009-09-23 2012-08-01 Protiva Biotherapeutics Inc. Compositions and methods for silencing genes expressed in cancer
JP4717961B2 (en) * 2009-10-07 2011-07-06 パナソニック株式会社 Artificial lipid membrane formation method
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP2496700B1 (en) 2009-11-04 2017-03-01 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
WO2011141705A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
EP2582387A2 (en) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CN103327963A (en) 2010-07-06 2013-09-25 诺华股份有限公司 Cationic oil-in-water emulsions
CN107090456A (en) 2010-08-02 2017-08-25 瑟纳治疗公司 The connection albumen led using the mediated rnai of short interfering nucleic acid(Cadherin related protein matter), the suppression of the gene expressions of β 1
US20130210663A1 (en) 2010-08-04 2013-08-15 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of cancer
CN103140582A (en) 2010-08-24 2013-06-05 默沙东公司 Single-stranded rnai agents containing an internal, non-nucleic acid spacer
EP2609106A4 (en) 2010-08-26 2014-03-19 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc Rna interference-mediated inhibition of gene expression using short interferring nucleic acids (sina)
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP3354644A1 (en) 2011-06-08 2018-08-01 Translate Bio, Inc. Cleavable lipids
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
SI2717893T1 (en) 2011-06-08 2019-10-30 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
SG10201605512WA (en) 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
RU2649133C2 (en) 2011-07-06 2018-03-29 Новартис Аг Cationic oil-in-water emulsions
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
CN102973506B (en) * 2011-09-05 2015-06-03 中国科学院深圳先进技术研究院 Cationic liposome and preparation method thereof
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
PL2817287T3 (en) * 2012-02-24 2019-10-31 Arbutus Biopharma Corp Trialkyl cationic lipids and methods of use thereof
US9546128B2 (en) 2012-03-29 2017-01-17 Shire Human Genetic Therapies, Inc. Ionizable cationic lipids
EP2830596A4 (en) 2012-03-29 2016-04-13 Shire Human Genetic Therapies Lipid-derived neutral nanoparticles
JP6228191B2 (en) * 2012-05-23 2017-11-08 ジ・オハイオ・ステート・ユニバーシティ Lipid-coated albumin nanoparticle composition, method of making the same, and method of using the same
AU2013271392B2 (en) 2012-06-08 2018-02-15 Ethris Gmbh Pulmonary delivery of mRNA to non-lung target cells
RU2015128057A (en) 2012-12-12 2019-03-27 Те Брод Инститьют, Инк. Delivery, design and optimization of systems, methods and compositions for manipulation with sequences and applications in therapy
SG10201710488TA (en) 2013-06-17 2018-01-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Targeting and Modeling Diseases and Disorders of Post Mitotic Cells
RU2016101198A3 (en) 2013-06-17 2019-03-27
WO2014152774A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Methods and compositions for delivering mrna coded antibodies
PL2968586T3 (en) 2013-03-14 2019-01-31 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
JP6586075B2 (en) 2013-03-14 2019-10-02 トランスレイト バイオ, インコーポレイテッド Method for purifying messenger RNA
EP2971013A4 (en) 2013-03-15 2016-10-19 Univ British Columbia Lipid nanoparticles for transfection and related methods
US20140288149A1 (en) 2013-03-15 2014-09-25 Graham Lord Mir-142 and antagonists thereof for treating disease
LT2972360T (en) 2013-03-15 2018-09-10 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
JP2016525146A (en) * 2013-07-23 2016-08-22 プロティバ バイオセラピューティクス インコーポレイテッド Compositions and methods for delivering messenger RNA
CA2928040A1 (en) * 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Cns delivery of mrna and uses thereof
MX2016005239A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Mrna therapy for phenylketonuria.
CA2928078A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
US20160287724A1 (en) 2013-11-18 2016-10-06 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
KR101647178B1 (en) * 2013-11-28 2016-08-23 충남대학교산학협력단 Stabilized Plasmid-Lipid Particles Using polyethylen glycol-lipid composed of an Enzymatically Cleavable Linker or oligo-lysines
AU2014362248A1 (en) 2013-12-12 2016-06-16 Massachusetts Institute Of Technology Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
EP3080271A2 (en) 2013-12-12 2016-10-19 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
MX2016007324A (en) 2013-12-12 2017-03-06 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders.
MX2016007327A (en) 2013-12-12 2017-03-06 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components.
EP3556353A2 (en) 2014-02-25 2019-10-23 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US9833416B2 (en) * 2014-04-04 2017-12-05 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
JP6571679B2 (en) 2014-04-25 2019-09-04 トランスレイト バイオ, インコーポレイテッド Method for purifying messenger RNA
CN106659731A (en) 2014-05-30 2017-05-10 夏尔人类遗传性治疗公司 Topical compositions and methods for treating wounds
EA201692309A1 (en) 2014-06-24 2017-06-30 Шир Хьюман Дженетик Терапис, Инк. Stereochemically enriched compositions for delivery of nucleic acids
CA2953341A1 (en) 2014-06-25 2015-12-30 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
BR112016030852A2 (en) 2014-07-02 2018-01-16 Shire Human Genetic Therapies rna messenger encapsulation
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
CN107208095A (en) 2014-10-02 2017-09-26 普洛体维生物治疗公司 Composition and method for making hepatitis B virogene expression silencing
EP3226912A1 (en) 2014-12-05 2017-10-11 Rana Therapeutics Inc. Messenger rna therapy for treatment of articular disease
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3230452A1 (en) 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
JP2018511588A (en) 2015-03-19 2018-04-26 トランスレイト バイオ, インコーポレイテッド MRNA treatment for Pompe disease
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
RU2018101732A (en) 2015-06-18 2019-07-22 Дзе Брод Инститьют Инк. New crispr enzymes and systems
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
AU2016280893A1 (en) 2015-06-18 2018-01-18 Massachusetts Institute Of Technology CRISPR enzyme mutations reducing off-target effects
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3362555A1 (en) 2015-10-14 2018-08-22 Translate Bio, Inc. Modification of rna-related enzymes for enhanced production
CN109153980A (en) 2015-10-22 2019-01-04 布罗德研究所有限公司 VI-B type CRISPR enzyme and system
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075531A1 (en) 2015-10-28 2017-05-04 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3532103A1 (en) 2016-10-26 2019-09-04 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017177169A1 (en) 2016-04-08 2017-10-12 Rana Therapeutics, Inc. Multimeric coding nucleic acid and uses thereof
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
CN110382692A (en) 2016-04-19 2019-10-25 博德研究所 Novel C RISPR enzyme and system
AU2017257274A1 (en) 2016-04-19 2018-12-06 Sourav CHOUDHURY Novel CRISPR enzymes and systems
CN109642231A (en) 2016-06-17 2019-04-16 博德研究所 VI type CRISPR ortholog and system
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
AU2017286980A1 (en) 2016-06-30 2019-01-17 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
WO2018026866A1 (en) * 2016-08-03 2018-02-08 Neuropore Therapies, Inc. Lipid-substituted amino 1,2-and 1,3-diol compounds as modulators of tlr2 dimerization
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018170333A1 (en) 2017-03-15 2018-09-20 The Broad Institute, Inc. Novel cas13b orthologues crispr enzymes and systems
WO2018191388A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
WO2018191719A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipid delivery of therapeutic agents to adipose tissue
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
WO2018208728A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2018232017A1 (en) 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprising curons and uses thereof
JP2019052102A (en) * 2017-09-13 2019-04-04 株式会社東芝 Biodegradable compounds, lipid particles, the composition comprising a lipid particle, and kits
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
US20190133948A1 (en) * 2017-11-06 2019-05-09 Nitto Denko Corporation Fusogenic compounds for delivery of biologically active molecules
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US716675A (en) * 1902-06-16 1902-12-23 Pleasant H Hanes Jr Sliver-can.
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
EP0032578B1 (en) 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Process and dialysis-installation for the preparation of bilayer-vesicles and their use
US4598051A (en) 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5545412A (en) 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2645866B1 (en) 1989-04-17 1991-07-05 Centre Nat Rech Scient News lipopolyamines, their preparation and their use
JPH03126211A (en) * 1989-10-12 1991-05-29 Nippon Chemicon Corp Electrolyte for electrolytic capacitor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP2774417B2 (en) * 1991-08-07 1998-07-09 株式会社ディ・ディ・エス研究所 Branched sugar complexes and particulate carrier having a peptide backbone
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6001644A (en) 1991-12-17 1999-12-14 The Regents Of The University Of California Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
JP2731630B2 (en) 1992-02-19 1998-03-25 アイシス・ファーマシューティカルス・インコーポレーテッド Modulation of the oligonucleotide of cell proliferation
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
JP2854203B2 (en) * 1992-09-03 1999-02-03 株式会社ディ・ディ・エス研究所 Process for the preparation of liposomes
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
FR2714830B1 (en) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa A composition containing nucleic acids, preparation and uses.
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
JPH10506093A (en) 1994-06-22 1998-06-16 メガバイオス・コーポレイション Cationic amphiphilic compound
FR2722506B1 (en) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa A composition containing nucleic acids, preparation and uses
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
EP0840744A4 (en) 1995-06-07 1999-03-10 Genta Inc Phosphonic acid-based cationic lipids
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
CA2223088A1 (en) 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
EP1489184A1 (en) 1995-06-07 2004-12-22 Inex Pharmaceutical Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU5979296A (en) 1995-06-07 1996-12-30 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU707947B2 (en) 1995-07-21 1999-07-22 Promega Biosciences, Inc. Novel amide-based cationic lipids
US6339173B1 (en) 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
US6330349B1 (en) 1995-11-30 2001-12-11 Chromavision Medical Systems, Inc. Automated method for image analysis of residual protein
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
SE520727C2 (en) * 1996-03-04 2003-08-19 Ciba Sc Holding Ag Alkylfenylbisacylfosfinoxid and fotoinitiatorblandningar
US6284267B1 (en) * 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6034135A (en) 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US5877220A (en) 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US20030069173A1 (en) 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
EP1027033B1 (en) * 1997-05-14 2009-07-22 The University Of British Columbia High efficiency encapsulation of nucleic acids in lipid vesicles
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
AT355826T (en) * 1997-10-10 2007-03-15 Inex Pharmaceuticals Corp Method for the seculation of nucleic acids in lipid double layers
CA2271582A1 (en) * 1998-05-14 1999-11-14 Sean C. Semple Method for administration of therapeutic agents, including antisense, with repeat dosing
CA2335393C (en) * 1998-07-20 2008-09-23 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
US6018175A (en) * 1998-09-03 2000-01-25 Micron Technology, Inc. Gapped-plate capacitor
EP1114575B1 (en) * 1998-09-17 2002-05-08 Matsushita Electric Industrial Co., Ltd. Method and apparatus for feeding component, and method and apparatus for mounting component
JP4854853B2 (en) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション Transfection agents
WO2000062813A2 (en) 1999-04-20 2000-10-26 The University Of British Columbia Cationic peg-lipids and methods of use
US6696424B1 (en) * 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
AU769517B2 (en) * 1999-07-14 2004-01-29 Alza Corporation Neutral lipopolymer and liposomal compositions containing same
CA2397016C (en) * 2000-01-10 2011-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusale M Use of lipid conjugates in the treatment of disease
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US20020086849A1 (en) 2000-10-27 2002-07-04 Gulilat Gebeyehu Method for introducing antisense oligonucleotides into eucaryotic cells
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
WO2004078121A2 (en) * 2003-02-28 2004-09-16 Alza Coporation Liposome composition for reduction of liposome-induced complement activation
CN101291653B (en) * 2003-07-16 2012-06-27 普洛体维生物治疗公司 Lipid encapsulated interfering rna
EP1766035B1 (en) * 2004-06-07 2011-12-07 Protiva Biotherapeutics Inc. Lipid encapsulated interfering rna
CA2572439A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
US20060228406A1 (en) 2005-03-17 2006-10-12 Invitrogen Corporation Transfection reagent for non-adherent suspension cells
CN103380113B (en) 2010-11-15 2018-03-30 生命科技公司 Transfection reagent and its preparation and application containing amine

Also Published As

Publication number Publication date
AU2004272646B2 (en) 2011-11-24
CA2551022C (en) 2013-06-04
JP2007505954A (en) 2007-03-15
CN1882693B (en) 2012-08-15
US20050175682A1 (en) 2005-08-11
US8936942B2 (en) 2015-01-20
IL174315A (en) 2015-09-24
CN1882693A (en) 2006-12-20
WO2005026372A1 (en) 2005-03-24
KR20060120009A (en) 2006-11-24
EP1664316A4 (en) 2009-11-25
EP1664316A1 (en) 2006-06-07
US7803397B2 (en) 2010-09-28
NZ581166A (en) 2011-06-30
CA2551022A1 (en) 2005-03-24
IL174315D0 (en) 2006-08-01
AU2004272646A1 (en) 2005-03-24
IL241209A (en) 2019-02-28
IL264517D0 (en) 2019-02-28
JP4842821B2 (en) 2011-12-21
KR101164256B1 (en) 2012-07-10
US20110091525A1 (en) 2011-04-21
EP1664316B1 (en) 2012-08-29
NZ592917A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
DE602004030992D1 (en) Wirbelstangen-approximator
DE602004026407D1 (en) Histondeacetylase-hemmer
DE602004026619D1 (en) N-substituierte p-menthancarbonsäureamide
DE602004027618D1 (en) Mobil-ethernet
DE502004007735D1 (en) Flächiges implantat
DE602004027011D1 (en) Uziervorrichtung
DE502004011703D1 (en) N-heterocyclyl-phenylsubstituierte cyclische ketoenole
DE602004021472D1 (en) Pyrimiidinverbindungen
DE602004029242D1 (en) Pyrazolamidverbindungen
DE602004026918D1 (en) Adaptives fec-codewort-management
DE602004023924D1 (en) Ease-hemmer
DE602004003142D1 (en) Infusionsgerät
DE602004019681D1 (en) Tibiaknieprothese
DE602004008468D1 (en) Photoresistpolymerzusammensetzungen
EP1635758A4 (en) Orthodynamic rehabilitator
DE602004019446D1 (en) Positionssprengsystem
HK1091204A1 (en) Heteroarylcarbamoylbenzene derivative
DE602004029646D1 (en) Thiolselektive wasserlösliche polymerderivate
DE602004012071D1 (en) T-hilfe
EP1615948A4 (en) Immuno-amplification
DE502004001465D1 (en) Nicstic refill-system
DE602004020356D1 (en) Phenoxyessigsäurederivate
EP1664316A4 (en) Polyethyleneglycol-modified lipid compounds and uses thereof
GB0325956D0 (en) Novel compounds
GB0316290D0 (en) Novel compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed